CRVS - Corvus - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

123.4M

Cash

22.13M

Avg Qtr Burn

-5.245M

Short % of Float

3.31%

Insider Ownership

4.02%

Institutional Own.

45.07%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Soquelitinib (CPI-818) (ITK inhibitor) Details Cutaneous T cell lymphoma, Lymphoma, Cancer, Blood cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab (CPI-006) (Anti-CD73) Details Lung cancer, Renal cell carcinoma, Cancer, Non-small cell lung carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soquelitinib (CPI-818) (ITK inhibitor) Details Renal cell carcinoma, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ciforadenant (A2AR inhibitor) +/- ipilimumab and nivolumab Details Renal cell carcinoma, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab + pembrolizumab Details Head and neck cancer, Cancer, Non-small cell lung carcinoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soquelitinib (CPI-818) (ITK inhibitor) Details Atopic dermatitis, Skin disease/disorder	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab (CPI-0060 (B-cell activation) (CD73 inhibitor) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.